Copyright
©The Author(s) 2021.
World J Stem Cells. May 26, 2021; 13(5): 386-415
Published online May 26, 2021. doi: 10.4252/wjsc.v13.i5.386
Published online May 26, 2021. doi: 10.4252/wjsc.v13.i5.386
PCDs | SCs | Molecular pathways of PCDs | Therapeutic target(s) | Therapeutic effects | Ref. |
Apoptosis | hESCs | Mitochondrial priming and p53 signaling pathway | Bcl-2 | Preventing damaged cells from compromising the genomic integrity of the population | [119] |
HSCs | ASPP1 stimulated p53 signaling pathway | ASPP1, RUNX1 | Preventing hematological malignancies | [120] | |
ISCs | ARTS/XIAP/caspase 9 axis | XIAP | Controlling ISC numbers and preventing the propagation of abnormal progeny | [121] | |
MSCs | p38 MAPK regulated early apoptosis while JNK regulated late apoptosis | p38 | Protecting MSCs from oxidative stress damage | [38] | |
NSCs | p38 MAPK signaling | TNF-α, p38 | Impairing cell viability, decreasing therapeutic effects | [122] | |
Autophagy | iPSCs | AMPK/mTOR/ULK1 complex/PI3K complex/conjugation cascade complexes with LC3 and Atg9 during macroautophagy;KFERQ domain/Hsc 70/LAMP2A during CMA | LC3 | Removing unnecessary or dysfunctional components | [123] |
HSCs | type III PI3K mammalian Atg6/PIP3/(Atg12-Atg5-Atg16) or (Atg4/LC3-I/Atg7/Atg3/LC3-II/PE) axis | LC3-II | Recycling cytoplasmic constituents and restoring metabolic homeostasis, and maintaining cells survival under harsh conditions | [124] | |
NSCs | PI3K-AKT-mTOR/ULK1/the class III PI3-kinase-Beclin1 complex/PI3/PI3P/ the complex of Atg12–Atg5–Atg16L1/LC3-I/LC3-II axis | mTOR | Being involved in modulation of the embryonic neurogenesis as well as the injury repair of adult brain | [125] | |
MSCs | PI3K/AKT/mTOR/ULK1/the class III PI3-kinase-Beclin1 complex/PI3/PI3P/the complex of Atg12–Atg5–Atg16L1/LC3-I/LC3-II axis | AKT, mTOR | Eliminating damaged organelles and biomacromolecules to maintain cellular homeostasis | [126,127] | |
ESCs | AMPK/ mTORC1/ULK1 axis | Atg5, Atg12 | Maintaining the undifferentiated state of ESCs in vitro | [128] | |
Necroptosis | ISCs | ZBP1/RIP3/MLKL axis | ZBP1 | Disrupting homeostasis of the epithelial barrier and promoting bowel inflammation | [35,129] |
SSCs | RIP1 signaling pathway | RIP1 | Using Nec-1 to target RIP1 for reducing both necroptosis and apoptosis, which benefits for recovery rate and proliferation potential | [130] | |
NPSCs | RIPK1/RIPK3/MLKL axis | HSP90 | Protecting SCs from PCD via alleviating mitochondrial dysfunction (mitochondrial membrane potential loss and ATP depletion) and oxidative stress (production of mitochondrial ROS), cellular total ROS and MDA, and downregulation of superoxide dismutase | [131] | |
Pyroptosis | MSCs | Exosome/circHIPK3/ FOXO3a axis | circHIPK3 | Preventing pyroptosis and repairing ischemic muscle injury through a novel exosome | [132] |
ESCs | Caspase-1 signaling pathway | N/A | Embryonic stem cell-derived exosomes inhibit doxorubicin-induced pyroptosis | [133] | |
Ferroptosis | NPCs and IPSCs | Ferritin/ROS/lipid peroxidation axis | NCOA4, p53 | Decreasing stem cells and triggering neuronal death | [134] |
- Citation: Hu XM, Zhang Q, Zhou RX, Wu YL, Li ZX, Zhang DY, Yang YC, Yang RH, Hu YJ, Xiong K. Programmed cell death in stem cell-based therapy: Mechanisms and clinical applications. World J Stem Cells 2021; 13(5): 386-415
- URL: https://www.wjgnet.com/1948-0210/full/v13/i5/386.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v13.i5.386